Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Regarding the claims that "no progress or accomplishments" have occurred this past year for progression of Covid-19 Phase II trials...and other trials LEO PR'd which he indicated (PR'd) he intended to proceed on...Ulcerative Colitis and oral mucositis
See PR summary below
Quote:
" Leo believes there might be more trials needed past the 120... Now we find out sites are not ready with visits pending... Also, no news on the overseas application... This is looking more and more like classic IPIX failure... They've struck out with financing and now the operation..."
1. If Leo "believes" there might be "more trials needed" after Phase II, that means PHASE II was a "SUCCESS". If a SUCCESS...money, grants even partnerships...lots of money will flow...because the efficacy as a therapeutic will have been confirmed. Yippie!!!
2. We don't know sites are "not ready" ... SITES ARE NOT ANNOUNCED YET!...IMO as per Leo's MO...We may hear something as soo as next week
3. No News on Overseas Application likely does not require announcement yet (21 days for notice)
4. IPIX/BRILACIDIN looks like a Failure... How dramatic! The outline below portents continued SUCCESS...IMO a short time away from MOA.protocols...multiple PR's for multiple indications.
5. Receiving $3M in stock sale (financing if you want to refer to it as that) to obviously support other indications previously reported UC and OM as PR'd...indicates more good new on the horizon...NOT FAILURE ...only a means to accomplish more...which I am sure will be PRs (use of $)
Brilacidin has NEVER FAILED a CLINICAL TRIAL...KNOW WHAT YOU OWN!
-------------------------------------------------------------------
I am looking forward to the coming year. New investors need to read the PR's from the initial 2/18/2020 announcement of Brilacidin for Covid 19 to the announcement of human clinical trials on 12/21/2020.
What they will find is a logical progression of basic scientific research where each success is built upon leading to additional study and success until the clinical trial announcement.In vitro testing conclusively demonstrates Brilacidin is one of the most promising therapeutics for Covid 19. This body of work is leading to human clinical trials where Brilacidin will be given to humans sick with Covid 19. It is a remarkable achievement for such a small company
http://www.ipharminc.com/press-release
-2/18 Initial announcement of Brilacidin for Covid 19
-2/24 Material transfer agreements to virology labs
-2/28 Brilacidin sent to Regional Biodefense Labs {RBL)for study
-3/2 Brilacidin PDF outlines scientific rationale for use against Covid19
-3/9 Brilacidin studies planned at RBL
-3/12 Testing to begin 3/16
-4/1 Brilacidin effective against Covid19 in Vero monkey cells
-4/6 Early discussions of human trials
-4/20 Screening of 11,552 compounds shows Brilacidin a leading drug against Covid19 by inhibiting the M-protease
-4/27 Initial research confirms anti Covid properties more research planned
-5/5 PHRI studies announced
-5/19 Brilacidin reduces Covid 75% in preincubtion Vero cell study
-5/26 Brilacidin reduces Covid in human renal cell line; blocks viral cell entry
-6/11 Brilacidin study to include MERS and SARS pan corona virus testing; Grant application application made
-6/17 Brilacidin inhibits Covid 97% in infected Human respiratory cells
-7/7 Brilacidin active against Covid 19 before during and after Covid infects cells
-7/13 Human clinical trial planning/manufacture of Brilacidin announced
-7/20 Brilacidin at low dosage is effective against Covid19; lower than ABSSI dose
-8/4 Brilacidin shown effective against entire Covid life cycle
-8/24 Brilacidin Selectivity index among highest reported
-8/26 Dr Degrado announced as science advisor
-9/15 Brilacidin synergistic with remdesivir;reduces viral load almost 100%
-10/2 Pre IND meeting; Brilacidin human clinical trials
-10/30 RBL preprint article released; Selectivity index 426 one of highest achieved
-11/2 FDA pre IND response received;CRO secured
-11/16 Overseas CTA submitted;Brilacidin viral resistance unlikely
-11/30 New research for Brilacidin as a pancoronavirus treatment
FDA application submitted
-12/21 Brilacidin for phase 2 Covid study approved
Where some see lies and deceit, I see scientific advancement,diligence and competence resulting in success.
GLTA including some friends,
Farrell
If you and others would read the PR's you would understand the CRO has been hired.
"Contract Research Organizations have been secured to expedite trial enrollment with many clinical sites expressing interest in participating in the study."
http://www.ipharminc.com/press-release/2020/11/2/innovation-pharmaceuticals-receives-pre-ind-response-from-fda-on-covid-19-trial
The CRO is responsible for the sites as well as the other arrangements for the human clinical trials.
Did you really expect Leo to fly around and make the arrangements? No wonder you seem so confused.
GLTA Farrell
I missed the volume call this week.It allowed me to pick up more cheap shares. I expect the market will respond to the announcements of the clinical trial sites and protocols. The .Keep your eyes open!
GLTA, Farrell
Keep your eyes open. A lot of news is on the way as the human clinical trials roll out.
If you read and comprehend the PR's you would know what to expect.
JMO,
Farrell
2021 IRA tucked away in IPIX shares at .175.
Next 2-3 weeks promise to be exciting.
Happy New Year... Happy 2021,
GLTA Farrell
Ball's palsy... kinda of like the flag is at half mast?
GLTA,
Farrell
Ivermecten review update 1/4/2021:
Ivermecten has severe challenges to overcome before it will be recommended as a drug for Covid19. In spite of some favorable in vitro data and encouraging results in small clinical trials, serious concerns demonstrated include drug interactions, toxic dosing requirements and neurotoxicity.
https://www.medscape.com/answers/2500114-197513/what-is-the-role-of-the-antiparasitic-drug-ivermectin-in-the-treatment-of-coronavirus-disease-2019-covid-19
"Available pharmacokinetic data from clinically relevant and excessive dosing studies indicate that the SARS-CoV-2 inhibitory
concentrations for ivermectin are not likely attainable in humans."
"They also raise concerns regarding ivermectin-associated neurotoxicity, particularly in patients with a hyperinflammatory state possible with COVID-19. In addition, drug interactions with potent CYP3A4 inhibitors (eg, ritonavir) warrant careful consideration of coadministered drugs. Finally, evidence suggests that ivermectin plasma levels with meaningful activity against COVID-19 would not be achieved without potentially toxic increases in ivermectin doses in humans. More data are needed to assess pulmonary tissue levels in humans."
"The authors note that this preliminary study does not translate to human use and the effective dose is not established at this early stage of discovery. More research is needed to determine if an antiviral effect would be elicited in humans, as the concentrations tested were much higher than what is achieved from the normal oral dose."
The good news regarding Ivermecten:
The ICON (Ivermectin in COvid Nineteen) retrospective cohort study (n = 280) in hospitalized patients with confirmed SARS-CoV-2 infection at 4 Florida hospitals showed significantly lower mortality rates for ivermectin (n = 173) compared with usual care (n = 107) (15% vs 25.2%; P = 0.03). The mortality rate was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%; P = 0.001), although the rate of successful extubation did not differ significantly.
GLTA,
Farrell
Good point. Earlier in the fall when the trials were being planned the Covid numbers were fluctuating at different geographic sites. Unfortunately the numbers of Covid cases now seems to be increasing everywhere,here and abroad.
My guess is the geographic diversity of the sites was to protect from a down turn in the number of cases at several sites which would impact the number of cases eligible for study.
In retrospect it appears that precaution is proving to be unnecessary.
The increase in the number of cases does reinforce the need for better treatments and a better antiviral.
Hopefully Brilacidin will be effective.
GLTA,Farrell
Thanks for posting. I had reviewed a short blurb online but this was a better description of the results
By the time the pandemic is under control we should have a better understanding of not only factors placing individuals at higher risk, but treatment initiation depending on the patients individual risk profile. As research continues a number of diverse risks should be identified.
The finding interferon may be helpful for Covid 19 contradicts the WHO study,but interferon was found helpful in several MERS coronavirus studies.
https://pubmed.ncbi.nlm.nih.gov/23620378/
https://www.jci.org/articles/view/126363
It may be an issue of timing and genetic risk.
GLTA Farrell
Look for an increase in volume next week.
GLTA Farrell
The beginning of the human clinical trials means the delays from the FDA and RBL are in the past and I agree with you things will start to move more quickly and predictably now.
Nice post. Hopefully your price predictions will prove reliable too.
GLTA Farrell
Aprea down 75%. Bad news for them.
Now that the Roche p53 drugs have also faded,it makes Kevetrin one of the few candidates for a p53 cancer drug.
Many cancer patients have p53 mutations. I sincerely hope Ipix can find the funds to fully study Kevetrin. A functioning p53 drug has the potential to help so many.
Glta Farrell
I am looking forward to the coming year. New investors need to read the PR's from the initial 2/18/2020 announcement of Brilacidin for Covid 19 to the announcement of human clinical trials on 12/21/2020.
What they will find is a logical progression of basic scientific research where each success is built upon leading to additional study and success until the clinical trial announcement.In vitro testing conclusively demonstrates Brilacidin is one of the most promising therapeutics for Covid 19. This body of work is leading to human clinical trials where Brilacidin will be given to humans sick with Covid 19. It is a remarkable achievement for such a small company
http://www.ipharminc.com/press-release
-2/18 Initial announcement of Brilacidin for Covid 19
-2/24 Material transfer agreements to virology labs
-2/28 Brilacidin sent to Regional Biodefense Labs {RBL)for study
-3/2 Brilacidin PDF outlines scientific rationale for use against Covid19
-3/9 Brilacidin studies planned at RBL
-3/12 Testing to begin 3/16
-4/1 Brilacidin effective against Covid19 in Vero monkey cells
-4/6 Early discussions of human trials
-4/20 Screening of 11,552 compounds shows Brilacidin a leading drug against Covid19 by inhibiting the M-protease
-4/27 Initial research confirms anti Covid properties more research planned
-5/5 PHRI studies announced
-5/19 Brilacidin reduces Covid 75% in preincubtion Vero cell study
-5/26 Brilacidin reduces Covid in human renal cell line; blocks viral cell entry
-6/11 Brilacidin study to include MERS and SARS pan corona virus testing; Grant application application made
-6/17 Brilacidin inhibits Covid 97% in infected Human respiratory cells
-7/7 Brilacidin active against Covid 19 before during and after Covid infects cells
-7/13 Human clinical trial planning/manufacture of Brilacidin announced
-7/20 Brilacidin at low dosage is effective against Covid19; lower than ABSSI dose
-8/4 Brilacidin shown effective against entire Covid life cycle
-8/24 Brilacidin Selectivity index among highest reported
-8/26 Dr Degrado announced as science advisor
-9/15 Brilacidin synergistic with remdesivir;reduces viral load almost 100%
-10/2 Pre IND meeting; Brilacidin human clinical trials
-10/30 RBL preprint article released; Selectivity index 426 one of highest achieved
-11/2 FDA pre IND response received;CRO secured
-11/16 Overseas CTA submitted;Brilacidin viral resistance unlikely
-11/30 New research for Brilacidin as a pancoronavirus treatment
FDA application submitted
-12/21 Brilacidin for phase 2 Covid study approved
Where some see lies and deceit, I see scientific advancement,diligence and competence resulting in success.
Good luck to all,
Farrell
Brilacidin in the clinical studies will be not be judged how effective it is against the in vitro results , but against the current therapies for Covid19.
It is safe to say current antiviral therapies against Covid 19 are poor.
After the World Heath Organization reviewed the Remdesivir data they said it produced no improvement in mortality. Yet, it appears to be the antiviral of choice in many US hospitals.
https://www.bmj.com/content/371/bmj.m4057
Eli Lilly's and Regeneron monoclonal antibody drugs have not been shown to improve mortality in Covid 19. In fact Lilly's drug made the more ill patients worse.Regeneron's drug may be more effective but in large groups of patients the fatality rate has been unchanged.
https://www.fiercepharma.com/pharma/covid-antibody-drugs-from-lilly-and-regeneron-won-t-do-much-to-boost-top-lines-analysts
https://www.washingtonpost.com/politics/2020/11/24/health-202-coronavirus-survival-rates-united-states-havent-improved-since-summer/
The bar for Brilacidin's success is very low in Covid 19. If it can achieve half of the success it did in vitro it will be a resounding success treating Covid 19.
GLTA Farrell
If you read the PRs carefully you would understand the CRO has been working. The sites will be treating patients when the final details are in place which will be soon.
Glta, Farrell
First patients to be treated soon. Next PR's will outline site details and protocols
Unfortunately lots of Covid patients. Study should be very quick. We should know if Brilacidin works soon. We could get initial report in 6 -8 weeks.
Congratulations to the longs for hanging in there. Still time to get full position while shares are cheap.
Farrell
Dexamethasone and Remdesivir have become the standard treatment for Covid 19 when more serious,usually pulmonary, symptoms are developing. Regeneron's antiviral monoclonal antibodies, Convalescent plasma, anticoagulants and appropriate general medical supporting care are given for disease progression.
You are right we need better treatments.
We need Brilacidin to work.
Glta Farrell
I am not aware of the RBL recommending a specific dose.The RBL reports do suggest a lower dose for the Covid trial than was used in ABSSSI 2b trial.Calculating drug doses from in vitro data is tricky,but the ABSSI data will be very helpful in calculating the Covid study dose.
https://www.fda.gov/media/72309/download
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529745/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742935/
Consulting companies are available to calculate trial doses.
https://www.nuventra.com/
"The new data, using the same assay method, reveal Brilacidin exhibited a similarly potent inhibitory effect against SARS-CoV-2 at an even lower concentration in the same human lung epithelial cell line. Brilacidin achieved approximately 90 percent inhibition of SARS-CoV-2 at a drug concentration that was one-half lower than previously tested. The lowest concentration of Brilacidin used in RBL testing to date is well below the clinically-achievable concentration based on the pharmacokinetics observed in the Company’s Phase 2b clinical trial of Brilacidin in Acute Bacterial Skin and Skin Structure Infections."
http://www.ipharminc.com/press-release/2020/7/20/innovation-pharmaceuticals-brilacidin-inhibits-novel-coronavirus-covid-19-by-almost-90-at-the-lowest-concentration-tested-to-date-in-a-human-lung-cell-line
Of note, the IC50(0.565µM) and IC90(2.63µM) values for brilacidin observed in the Calu-3 cell line are well below clinically-achievable concentrations based on pharmacokinetics observed in a Phase 2b clinical trial of brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): median Cmax in plasma was 7.67µM brilacidin (free-base) from a single IV dose of 0.6 mg/kg.
http://www.ipharminc.com/new-blog/2020/10/30/preprint-brilacidin-a-covid-19-drug-candidate-exhibits-potent-in-vitro-antiviral-activity-against-sars-cov-2
Is a ventilator available for you if you develop pulmonary failure from Covid?
Google... How full is the ICU near me?
Hit the link then put in your zip code.
It is horrifying
Stay safe,
Farrell
It is going to take months and millions of infections before Covid is brought under control.The infection rate here and around the world is at an all time high. Covid patients are filling up hospitals and ICUs around the country.
https://www.nytimes.com/interactive/2020/12/09/us/covid-hospitals-icu-capacity.html
https://www.reuters.com/article/us-health-coronavirus-usa/fauci-slight-coronavirus-spikes-may-get-out-of-control-amid-u-s-reopening-idUSKBN23J3AI
Brilacidin for Covid will be welcome.
Glta, Farrell
One of these days... Bang Zoom... its going to the moon!
Scientific Advisor, Drug Discovery and Clinical Development
Thanks for posting. I was not aware he had been granted the additional titles of "Drug Discovery and Clinical Development".
It would be interesting to know what he has been up to on IPIX's behalf.
GLTA,Farrel
Perhaps Mr Ehrlich was looking for a way of securing financing until the grant money rolls in.
In the chorus to point out all the negatives to the recent financing, you are the only one to point out this very likely positive possibility. Why is that?
The other possibility is he had an opportunity to secure financing for Brilacidin for Ulcerative Colitis in a way which would allow that trial to continue regardless of the outcome of the Covid clinical trial. Think of it as an insurance policy.
GLTA Farrell
http://www.edgarmaster.com/Inet/main/DataFeedHtml1.jsp
"Following 90 days after the second closing, the Company may elect to redeem the preferred stock for 120% of the aggregate stated value then outstanding, plus all accrued but unpaid dividends and all liquidated damages and other amounts due in respect of the preferred stock. The Company’s right to redeem the preferred stock is contingent upon it having complied with a number of conditions, including compliance with its obligations under the Certificate of Designation. Shares of preferred stock will generally have no voting rights, except as required by law and except that the Company shall not take certain actions without the consent of the holders of the preferred stock."
If Brilacidin for Covid 19 works as well in Covid patients as it it did in the test tube its value becomes almost incalculable. Virtually every country in the world is struggling with not only a pandemic health crisis but an economic catastrophe costing trillions of dollars.
Remember the EU paid over a billion dollars for 500,000 Remdesivir treatment courses {does Remdesivir even work?}
https://www.reuters.com/article/us-health-coronavirus-eu-remdesivir/eu-makes-1-billion-euro-bet-on-gileads-covid-drug-before-trial-results-idUSKBN26Y25K
If Brilacidin really works you can multiple that figure by several double digit multiples just for Europe;then multiply that result by several additional multiples for each geographic area on earth. Then add some for short covering and a bidding war.
At that point Brilacidin's valuation will easily exceed the vaccine valuations.
If Brilacidin works the cost would be justified. What is it worth to the world wide economy for people to be able to go to work without fearing for their health or their familliy's well being?
Imagine traveling without fear, eating out, having a drink with friends at the bar,attending a religious service,weddings, funerals, class reunions, visiting mom at the nursing home. Covid has cost us a lot and we will gladly pay to restore our lives.
In my opinion we are going to know if Brilacidin is part of the answer in a few weeks.
GLTA,Farrell
Post of the day.
Patience is required. Investors have to realize there is a much activity behind the scenes.
My bet is IPIX's course will be very clear ,very soon.
Go IPIX, Farrell
I agree with both you and Dane. The human clinical trials could be announced at any time. It is my understanding the foreign trials are associated with less paper work and are likely to start first...perhaps even before the FDA issues an approval of Brilacidin's application.
The 8K announcement of the 5 million of additional funding produced interesting trading and opinions. We will have to wait to see what IPIX's plans are for the funding, but my bet it is to produce more Brilacidin for both the Covid trial and the Ulcerative Colitis trial.
I view the increased funding as a positive event even though I am well aware of the downside of convertible preferred financing.
IPIX shareholders can expect a series of positive announcements between now and the end of the year.
We should know the facts soon.
GLTA Farrell
Thanks for posting. Interesting site.
GLTA Farrell
Best wishes for a quick and complete recovery for you and your family.
Farrell
I am hoping for an exceptionally merry Christmas!
GLTA Farrell
Next big news should be the announcements of human clinical Phase 2 human clinical trial protocols, sites ,dates. I look forward to Dr William Degrado's efforts and dreams to be fulfilled
CRO has been working hard for over a month:
Nov 2 PR
"Contract Research Organizations have been secured to expedite trial enrollment with many clinical sites expressing interest in participating in the study. The Company anticipates commencing the Brilacidin for COVID-19 clinical trial in 4Q2020."
July 7 PR
"Steps have begun with the Contract Development and Manufacturing Organization (CDMO) in preparation for upcoming manufacture of the drug product for COVID-19 clinical trial use, to be followed by interactions with relevant Health Authorities to obtain input and guidance on trial design.”
Nov 16 PR
"Sufficient Brilacidin intravenous (IV) drug product has been manufactured to complete this trial, and potentially future COVID-19 trials, providing the Company with added flexibility as it develops Brilacidin for the treatment of COVID-19."
Aug 26 news release
https://www.globenewswire.com/news-release/2020/08/26/2084130/0/en/Dr-William-F-DeGrado-a-Discoverer-of-Brilacidin-Joins-Innovation-Pharmaceuticals-as-Scientific-Advisor.html
" “I am excited to be involved again with Brilacidin, a unique biomimetic drug candidate that has been properly advanced clinically by Innovation across multiple indications,” said William F. DeGrado, PhD, Professor in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF). “I look forward to collaborating with the Innovation team—most urgently, toward developing Brilacidin as a promising therapeutic to treat the novel coronavirus and possibly other viruses. Brilacidin already has exhibited intriguing anti-SARS-CoV-2 in vitro inhibitory efficacy at clinically-achievable concentrations based on Brilacidin pharmacokinetics seen in earlier clinical testing. The world is in dire need of new antiviral treatments and Brilacidin is well-positioned potentially to emerge as one.”
That is a lot of positive news in just a few months,isn't it?
GLTA Farrell
My guess the IND was filed within a day or 2 of 11/20.
11/16 "...with a U.S. Investigational New Drug (IND) application also to be submitted this week to the FDA."
11/30 "In related news, requisite documentation has been filed with the appropriate regulatory agencies, including an Investigational New Drug application (IND) with the FDA, for conduct of a multinational Phase 2 clinical trial of Brilacidin in patients hospitalized with COVID-19."
GLTA, Farrell
Anyone worried about Brilacidin coming out after the Covid19 epidemic is over need not worry. Unfortunately no area in the US or overseas is being spared.
If Brilacidin works as well in the human clinical trials as it did in vitro it will be widely available early next year.
Just pray it works.
GLTA,Farrell
Between now and the interim human trial report IPIX investors can expect a series of positive PR's which will outline Brilacidin's FDA review, foreign and domestic human clinical plans,
clinical trial protocols, and other details which will lead to press coverage in anticipation of the interim trial report.
Covid 19 is a worldwide scourge which is destroying individual health, health care systems and economies. Unfortunately we are on the verge of expotenial spread of Corona virus which will tax much of the nations health facilities much in the same way New York City and Italy was tested early in the pandemic. If Brilacidin's human trials confirm the in vitro testing it will be the Coronavirus antiviral of choice and a cornerstone of any Covid19 treatment regimen.
The next 6 weeks are going to be exciting for Ipix shsreholders.
Jmo
Glta, Farrell
Post of the week!!
Glta Farrell
"Systemic adverse events were more common after the second vaccination, particularly with the highest dose, and three participants (21%) in the 250-µg dose group reported one or more severe adverse events."
Its in the NEJM article.
Farrell
I would love to put more cheap shares in my IRA on Jan 1st and at 16 cents a share...it would be a dream for me.
16 cent shares:
1. for a company about to enter human clinical trials,
2. after having arguably the best in vitro results for any Covid antiviral,
3. one of the highest SI's over 400,
4. independent government lab validation,
5. late stage of FDA review,
6. stellar safety record with over 500 patients,
7. world renown scientific adviser, Dr Degrado, added to team after positive lab results,
8. published study results
Baby, my bets on the table. We will see who blinks first!
All for 16 cents. All I can say is:
Thank you very much,
GLTA, Farrell
m RNA vaccines such as Pfizer's and Moderna's vaccines have potential side effects.
Thanks for reminding use of the risks of Monoclonal antibody drugs
Rash, fever, fatigue, headache,or joint pain in up to 21% of patients
https://www.sciencemag.org/news/2020/11/fever-aches-pfizer-moderna-jabs-aren-t-dangerous-may-be-intense-some
https://www.nejm.org/doi/full/10.1056/nejmoa2022483
Autoimmune disease activation after mRNA documented in clinical trials:
"Several different mRNA vaccines have now been tested from phase I to IIb clinical studies and have been shown to be safe and reasonably well tolerated (TABLES 2,?,3).3). However, recent human trials have demonstrated moderate and in rare cases severe injection site or systemic reactions for different mRNA platforms22,91. Potential safety concerns that are likely to be evaluated in future preclinical and clinical studies include local and systemic inflammation, the biodistribution and persistence of expressed immunogen, stimulation of auto-reactive antibodies and potential toxic effects of any non-native nucleotides and delivery system components. A possible concern could be that some mRNA-based vaccine platforms54,166 induce potent type I interferon responses, which have been associated not only with inflammation but also potentially with autoimmunity167,168. Thus, identification of individuals at an increased risk of autoimmune reactions before mRNA vaccination may allow reasonable precautions to be taken. Another potential safety issue could derive from the presence of extracellular RNA during mRNA vaccination. Extracellular naked RNA has been shown to increase the permeability of tightly packed endothelial cells and may thus contribute to oedema169. Another study showed that extracellular RNA promoted blood coagulation and pathological thrombus formation170. Safety will therefore need continued evaluation as different mRNA modalities and delivery systems are utilized for the first time in humans and are tested in larger patient populations.
Will individuals with autoimmune diseases be treated with MRNA ?
"identification of individuals at an increased risk of autoimmune reactions before mRNA vaccination may allow reasonable precautions to be taken"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906799/
Why we can not rush a Covid19 vaccine.
https://www.aamc.org/news-insights/here-s-why-we-can-t-rush-covid-19-vaccine
GLTA farrell
Autoimmune disease activation associated with standard vaccinations
Autoimmune diseases reported after vaccination
Autoimmune disease Type of vaccine Ref
Systemic lupus erythematosus HBV, tetanus, anthrax [17]
Rheumatoid arthritis HBV, tetanus, typhoid/parathypoid, MMR [18]
Multiple sclerosis HBV [19–21]
Reactive arthritis BCG, typhoid, DPT, MMR, HBV influenza [22–24]
Polymiositis/ dermatomyositis BCG, smallpox, diphtheria, DPT [22, 25]
Polyarteritis nodosa Influenza, pertussis, HBV [22, 25]
Guillain-Barrè syndrome Influenza, polio, tetanus [26–28]
Diabetes mellitus-type I HIB [29–31]
Idiopathic thrombocytopenia MMR, HBV [22, 25]
Hashimoto thyroiditis HBV [32]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607155/
h
Terrific post should be stickied
Glta, Farrell
Just good detective work.
First hint is under Aarthi Narayanan at GMU in vitro Brilacidin studies confirmed one of the mechanisms of action is the virucidal effect of Brilacidin against Cornavirus.
Hint number 2 is this section of the report is titled "Rising to the Covid-19 challenge" pg 297 with Aarthi Narayanan featured under the title.
Hint 3 is the title of the page 307 is Case 2: Antiviral peptides and synthetic peptidomimetics against human coronaviruses –GMU...
To the best of my knowledge Brilacidin is the only synthetic peptidomimetic studied as a treatment against Coronavirus.
Hint 4 C titled Brilacidin–a human AMP peptidomimetic
Hint 5 B is a schematic of 3 Brilacidin molecules attaching to a viral capsid as you look from left to right you see the Brilacidin disrupting the membrane as more Brilacidin molecules attach the membrane is completely disrupted. A second schematic shows a blue viral capsid being disrupted.
Hint 6 An EM with 2 images ON the L is a cross section of the viral particle the on the R shows 2 disrupted viruses.
If you need any more help let me know.
GLTA Farrell
Ipix and Brilacidin making progress. I am looking forward to being in a better exchange. The shorters still control things here, but they should be very afraid.
Interim report still should be mid to end of December. We will know for sure then.
Glta, Farrell